 CytoDyn Inc OTCQB:CYDY plans to submit the topline results of its CD12 Phase 3 clinical trial of Vyrologix leronlimab-PRO 140 for severe to critically ill COVID-19 patients to regulatory agencies, including those in India and the Philippines. Patients in the CD12 trial were administered two doses of leronlimab, the first on day zero and another on day seven. 